<DOC>
	<DOCNO>NCT00835237</DOCNO>
	<brief_summary>This phase IIIb , observer-blind study evaluate immunogenicity safety GSK Biologicals ' Boostrix® vaccine adult ( extend indication ) age 65 year old .</brief_summary>
	<brief_title>Evaluation GlaxoSmithKline Biologicals ' Boostrix® Vaccine Comparison With Decavac™ Vaccine .</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . Males females 65 year age old time study entry . Free acute aggravation health status establish medical history medical history clinical examination enter study . Written inform consent subject . Administration diphtheriatetanus ( Td ) booster within previous 5 year . Administration Tdap vaccine time prior study entry . History diphtheria and/or tetanus and/or pertussis disease . Use investigational nonregistered drug vaccine study vaccine within 30 day precede vaccination , plan use entire study period . Administration license vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior enrolment study , exception influenza , vaccine , may administer time study period , include day study vaccination . Planned administration vaccine foreseen study protocol 30 day follow vaccination , exception influenza , vaccine , may administer time study period , include day study vaccination . Pneumococcal zoster vaccine administer discretion investigator subject come back Visit 2 . Chronic administration immunosuppressant immunemodifying drug within six month prior vaccination plan administration study period . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination . History serious allergic reaction follow tetanus toxoid , diphtheria toxoid pertussiscontaining vaccine component study vaccine . History encephalopathy within seven day administration previous booster dose pertussis vaccine attributable another identifiable cause . Progressive neurologic disorder , uncontrolled epilepsy progressive encephalopathy : pertussis vaccine administer individual condition treatment regimen establish condition stabilize . Acute ( active ) clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine clinical evaluation preexist laboratory screening test . Acute disease time vaccination . Administration immunoglobulins and/or blood product within three month precede vaccination , plan administration study period . Any medical condition , opinion investigator , might interfere evaluation require study .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Boostrix®</keyword>
	<keyword>adult</keyword>
</DOC>